JAMES KENNY: Open Payments
NPI 1700350238 · FALL RIVER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,219 in 61 payments from 16 companies in 2025. Trend: 2023 $1,776 · 2024 $1,701 · 2025 $1,219
Food & beverage: $1,219
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $267 |
| GlaxoSmithKline, LLC. | 11 | $168 |
| GENZYME CORPORATION | 11 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Merck Sharp & Dohme LLC | 4 | $97 |
| Mallinckrodt Hospital Products Inc. | 3 | $74 |
| United Therapeutics Corporation | 2 | $62 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| INOGEN, INC. | 2 | $43 |
| Insmed, Inc. | 2 | $43 |
Products named: FASENRA, DUPIXENT, GLASSIA, BREZTRI, ZERBAXA, NUCALA, TRELEGY ELLIPTA, ACTHAR.
Industry payments across MA — which companies pay providers there.
